ESSA Pharma Inc. is a Canada-based pharmaceutical company that was previously focused on developing therapies for the treatment of patients with prostate cancer. The Company is undergoing a comprehensive review process to review its strategic options to maximize shareholder value.

Employees

Sector

Investment Holding Companies

More about the company

Market Closed - Nasdaq 23:00:00 08/10/2025 +03			5-day change	1st Jan Change
0.2012 ^USD	-1.85%		-.--%	-

09/10/25	Alexis Bio, Inc completed the acquisition of ESSA Pharma Inc. for $80.4 million.	CI
09/10/25	ESSA Pharma Inc.(NasdaqGM:EPIX) dropped from NASDAQ Composite Index	CI

Market Cap	9.04M 8.06M 7.51M 6.83M 12.87M 870M 12.97M 90.74M 35.31M 444M 33.92M 33.19M 1.43B	P/E 2023	-5.13x	P/E 2024	-9.4x
Enterprise Value	-117M -105M -97.57M -88.79M -167M -11.31B -168M -1.18B -459M -5.77B -441M -431M -18.55B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	100%	Yield 2023 *	-	Yield 2024	-

09/10/25	Alexis Bio, Inc completed the acquisition of ESSA Pharma Inc. for $80.4 million.	CI
09/10/25	ESSA Pharma Inc.(NasdaqGM:EPIX) dropped from NASDAQ Composite Index	CI
07/10/25	Essa securityholders approve acquisition by XenoTherapeutics	RE
07/10/25	Essa securityholders approve acquisition by XenoTherapeutics	RE
07/10/25	ESSA Pharma Shareholders Approve Acquisition by XenoTherapeutics	MT
04/10/25	ESSA Pharma Inc. - Shareholder/Analyst Call
01/10/25	Essa Pharma provides update on its application to the Supreme Court of British Columbia for amended interim order	RE
24/09/25	Essa Pharma amends agreement with XenoTherapeutics	RE
24/09/25	Essa Pharma amends agreement with XenoTherapeutics	RE
22/09/25	ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index	CI
10/09/25	Essa Pharma to adjourn special meeting to September 29, 2025	RE
13/08/25	ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
06/08/25	Essa Pharma Inc. Announces Cash Distribution, Payable on August 22, 2025	CI

01/10/25	Essa Pharma provides update on its application to the Supreme Court of British Columbia for amended interim order	RE
04/11/24	Oppenheimer Downgrades ESSA Pharma to Market Perform	MT
04/11/24	Piper Sandler Downgrades ESSA Pharma to Neutral	MT
04/11/24	Jefferies Downgrades ESSA Pharma to Hold, Price Target is $1.70	MT
14/12/22	Oppenheimer Adjusts ESSA Pharma's Price Target to $17 From $23, Maintains Outperform Rating	MT

ESSA Pharma Inc. Stock

Stocks

EPIX

CA29668H7085

Investment Holding Companies

Valuation: ESSA Pharma Inc.

Chart: ESSA Pharma Inc.

Latest news: ESSA Pharma Inc.

Last Transcript: ESSA Pharma Inc.

Analysts' recommendations: ESSA Pharma Inc.

Press Releases: ESSA Pharma Inc.

News in other languages: ESSA Pharma Inc.

Quotes and Performance

Price Extremes

Managers and Directors: ESSA Pharma Inc.

Latest insider transactions

Shell Companies

Financials

Company Profile

09/10/25	ESSA Announces Completion of Arrangement with XenoTherapeutics	AQ
25/08/25	Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution	AQ
25/08/25	Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution	PR
14/08/25	Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution	PR
13/08/25	ESSA Pharma: Fiscal Q3 Earnings Snapshot	AQ

1 year	0.19	0.22
3 years	0.18	11.67
5 years	0.18	14.88
10 years	0.18	71.8

Manager	Title	Age	Since
Jon Adkins PSD	President	-	09/10/2025
Han-Jie Zhou PRN	Corporate Officer/Principal	-	24/04/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/9/25 A	Richard Glickman	Issuer sale	Chairman	43,240	0.0974%
10/9/25 A	Scott Requadt	Issuer sale	Director	30,002	0.0676%
10/9/25 A	David Parkinson	Issuer sale	Chief Executive Officer	65,675	0.1480%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ESSA PHARMA INC.	-1.85%	-.--%	-2.38%	-93.16%	9.52M
INVESTOR AB	+1.67%	+0.67%	+31.43%	+92.41%	122B
INDUSTRIVÄRDEN AB	+1.44%	-1.95%	+37.55%	+84.58%	22.27B
HAL TRUST	+0.86%	-0.12%	+22.29%	+51.29%	16.52B
MERITZ FINANCIAL GROUP INC.	+1.26%	-3.45%	+13.58%	+143.48%	15.44B
LUNDBERG B	+1.46%	-2.31%	+14.17%	+24.32%	13.93B
KINGDOM HOLDING COMPANY	+2.74%	+2.89%	+69.27%	+98.57%	13.34B
INVESTMENT AB LATOUR	+2.33%	+2.27%	-10.77%	+7.28%	12.85B
BAJAJ HOLDINGS & INVESTMENT LIMITED	-0.04%	-0.45%	-10.02%	+55.10%	12.27B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	+0.59%	-2.73%	+17.83%	+37.20%	12.01B
Average	+1.04%	-2.07%	+18.29%	+50.11%	24.09B
Weighted average by Cap.	+1.50%	-1.89%	+26.28%	+79.34%

	2023	2024
Net sales	-	-
Net income	-26.58M -23.71M -22.09M -20.11M -37.86M -2.56B -38.14M -267M -104M -1.31B -99.79M -97.64M -4.2B	-28.54M -25.46M -23.72M -21.59M -40.65M -2.75B -40.96M -287M -112M -1.4B -107M -105M -4.51B
Net Debt	-148M -132M -123M -112M -211M -14.25B -212M -1.49B -578M -7.27B -556M -544M -23.38B	-126M -113M -105M -95.63M -180M -12.18B -181M -1.27B -494M -6.21B -475M -464M -19.98B